atai Life Sciences Announces $50 Million Private Placement Financing
atai Life Sciences (NASDAQ: ATAI) has secured a significant $50 million private placement financing through the sale of 18,264,840 ordinary shares and pre-funded warrants for 4,566,210 additional shares. The financing round was co-led by Ferring Ventures S.A. and Apeiron Investment Group, with participation from healthcare-focused investors including Ally Bridge Group and ADAR1.
The company plans to use the proceeds for general corporate purposes, working capital, and advancement of its clinical development programs. The private placement, expected to close in Q3 2025, is subject to certain conditions, including HSR Act waiting period expiration.
This strategic investment positions atai to transition from a clinical-stage biotech into a commercial entity, with plans for FDA discussions and Phase 3 planning in early 2026. TD Cowen, Leerink Partners, Guggenheim Securities, and Berenberg are serving as joint-lead placement agents for this transaction.
atai Life Sciences (NASDAQ: ATAI) ha ottenuto un significativo finanziamento privato da 50 milioni di dollari attraverso la vendita di 18.264.840 azioni ordinarie e warrant pre-finanziati per ulteriori 4.566.210 azioni. Il round di finanziamento 猫 stato co-guidato da Ferring Ventures S.A. e Apeiron Investment Group, con la partecipazione di investitori specializzati nel settore sanitario, tra cui Ally Bridge Group e ADAR1.
L'azienda prevede di utilizzare i proventi per scopi societari generali, capitale operativo e l'avanzamento dei suoi programmi di sviluppo clinico. Il collocamento privato, che dovrebbe concludersi nel terzo trimestre del 2025, 猫 soggetto a determinate condizioni, inclusa la scadenza del periodo di attesa previsto dall'HSR Act.
Questo investimento strategico posiziona atai per la transizione da una biotech in fase clinica a un'entit脿 commerciale, con piani per discussioni con la FDA e la pianificazione della Fase 3 all'inizio del 2026. TD Cowen, Leerink Partners, Guggenheim Securities e Berenberg agiscono come agenti congiunti per il collocamento di questa operazione.
atai Life Sciences (NASDAQ: ATAI) ha asegurado un financiamiento privado significativo de 50 millones de d贸lares mediante la venta de 18,264,840 acciones ordinarias y warrants prefinanciados para 4,566,210 acciones adicionales. La ronda de financiamiento fue co-liderada por Ferring Ventures S.A. y Apeiron Investment Group, con la participaci贸n de inversores enfocados en el sector salud, incluyendo Ally Bridge Group y ADAR1.
La compa帽铆a planea usar los fondos para prop贸sitos corporativos generales, capital de trabajo y el avance de sus programas de desarrollo cl铆nico. La colocaci贸n privada, que se espera cierre en el tercer trimestre de 2025, est谩 sujeta a ciertas condiciones, incluyendo la expiraci贸n del per铆odo de espera bajo la HSR Act.
Esta inversi贸n estrat茅gica posiciona a atai para la transici贸n de una biotecnol贸gica en etapa cl铆nica a una entidad comercial, con planes para discusiones con la FDA y la planificaci贸n de la Fase 3 a principios de 2026. TD Cowen, Leerink Partners, Guggenheim Securities y Berenberg act煤an como agentes principales conjuntos para esta transacci贸n.
atai Life Sciences (NASDAQ: ATAI)電� 18,264,840欤检潣 氤错喌欤检櫠� 4,566,210欤检潣 於旉皜 欤检嫕鞐� 雽�頃� 靹犾旮� 鞗岆煱韸鸽ゼ 韱淀暣 5,000毵� 雼煬 攴滊鞚� 靷 鞛愱笀 臁半嫭鞚� 靹标车鞝侅溂搿� 頇曤炒頄堨姷雼堧嫟. 鞚措矆 鞛愱笀 臁半嫭 霛检毚霌滊姅 Ferring Ventures S.A.鞕赌 Apeiron Investment Group鞚� 瓿惦彊 欤茧弰頄堨溂氅�, Ally Bridge Group瓿� ADAR1 霌� 項姢旒�鞏� 鞝勲 韴瀽鞛愲摛霃� 彀胳棳頄堨姷雼堧嫟.
須岇偓電� 臁半嫭 鞛愱笀鞚� 鞚茧皹 氩曥澑 氇╈爜, 鞖挫爠鞛愲掣 氚� 鞛勳儊 臧滊皽 頂勲攴鸽灗 歆勳爠鞐� 靷毄頃� 瓿勴殟鞛呺媹雼�. 鞚� 靷 韴瀽電� 2025雲� 3攵勱赴 毵堦皭 鞓堨爼鞚措┌, HSR氩� 雽�旮� 旮瓣皠 毵岆 霌� 韸轨爼 臁瓣贝鞚� 於╈”霅橃柎鞎� 頃╇媹雼�.
鞚措矆 鞝勲灥鞝� 韴瀽電� atai臧� 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厤鞐愳劀 靸侅梾鞝� 旮办梾鞙茧 鞝勴櫂頃橂姅 雿� 欷戩殧頃� 鞙勳箻毳� 毵堧牗頃橂┌, 2026雲� 齑� FDA鞕赌鞚� 雲检潣 氚� 3靸� 瓿勴殟鞚� 於旍頃� 鞓堨爼鞛呺媹雼�. TD Cowen, Leerink Partners, Guggenheim Securities, Berenberg臧� 鞚� 瓯半灅鞚� 瓿惦彊 欤缄磤靷 頇滊彊頃橁碃 鞛堨姷雼堧嫟.
atai Life Sciences (NASDAQ : ATAI) a obtenu un financement priv茅 important de 50 millions de dollars par la vente de 18 264 840 actions ordinaires et de bons de souscription pr茅financ茅s pour 4 566 210 actions suppl茅mentaires. Ce tour de financement a 茅t茅 co-dirig茅 par Ferring Ventures S.A. et Apeiron Investment Group, avec la participation d'investisseurs sp茅cialis茅s dans le secteur de la sant茅, notamment Ally Bridge Group et ADAR1.
La soci茅t茅 pr茅voit d'utiliser les fonds pour des besoins g茅n茅raux d'entreprise, le fonds de roulement et l'avancement de ses programmes de d茅veloppement clinique. Le placement priv茅, qui devrait se cl么turer au troisi猫me trimestre 2025, est soumis 脿 certaines conditions, notamment l'expiration de la p茅riode d'attente selon la loi HSR.
Cet investissement strat茅gique positionne atai pour passer d'une biotech en phase clinique 脿 une entit茅 commerciale, avec des plans de discussions avec la FDA et de planification de la phase 3 d茅but 2026. TD Cowen, Leerink Partners, Guggenheim Securities et Berenberg agissent en tant qu'agents principaux conjoints pour cette op茅ration.
atai Life Sciences (NASDAQ: ATAI) hat eine bedeutende Privatplatzierung in H枚he von 50 Millionen US-Dollar durch den Verkauf von 18.264.840 Stammaktien und vorfinanzierten Warrants f眉r weitere 4.566.210 Aktien gesichert. Die Finanzierungsrunde wurde von Ferring Ventures S.A. und Apeiron Investment Group gemeinsam geleitet, mit Beteiligung von gesundheitsorientierten Investoren wie Ally Bridge Group und ADAR1.
Das Unternehmen plant, die Erl枚se f眉r allgemeine Unternehmenszwecke, Betriebskapital und die Weiterentwicklung seiner klinischen Entwicklungsprogramme zu verwenden. Die Privatplatzierung, die voraussichtlich im dritten Quartal 2025 abgeschlossen wird, unterliegt bestimmten Bedingungen, einschlie脽lich des Ablaufs der Wartefrist nach dem HSR-Gesetz.
Diese strategische Investition positioniert atai f眉r den 脺bergang von einem biotechnologischen Unternehmen in der klinischen Phase zu einem kommerziellen Unternehmen, mit Pl盲nen f眉r FDA-Gespr盲che und Phase-3-Planungen Anfang 2026. TD Cowen, Leerink Partners, Guggenheim Securities und Berenberg fungieren als gemeinsame leitende Platzierungsagenten f眉r diese Transaktion.
- Secured substantial $50 million in financing from prominent healthcare-focused investors
- Strategic backing from existing investors demonstrates continued confidence in company's direction
- Financing strengthens position for upcoming FDA discussions and Phase 3 planning
- Support from Ferring Ventures brings valuable commercialization and market expertise
- Shares and warrants issued in private placement are not registered under Securities Act, limiting immediate tradability
- Financing structure includes dilutive elements through new share issuance
- Transaction subject to regulatory approval under HSR Act, adding closing uncertainty
Insights
$50M private placement strengthens atai's financial position as it advances psychedelic therapies toward potential commercialization.
This
The investor composition is particularly noteworthy. The round is co-led by Ferring Ventures and Apeiron Investment Group (the family office of atai's Founder/Chairman Christian Angermayer), with participation from both new and existing healthcare-focused institutional investors. Ferring's expanded investment is strategically valuable beyond just capital 鈥� their expertise in commercialization and sales team development will be crucial as atai eventually transitions from clinical-stage to commercial operations.
Management's commentary suggests confidence in upcoming trial results that could support productive FDA discussions and establish a clear Phase 3 plan by early 2026. This timeline provides investors with a concrete developmental roadmap.
For a clinical-stage biotech company without product revenue, maintaining sufficient capital is essential. This financing strengthens atai's balance sheet while demonstrating continued investor confidence in both the company's pipeline and the broader potential of psychedelic therapies for mental health conditions. The placement's size relative to atai's market capitalization makes this a material development that reinforces the company's ability to reach key value-creating milestones.
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1
NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (鈥渁tai鈥�), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary shares of atai with a nominal value of
The financing was co-led by Ferring Ventures S.A. and Apeiron Investment Group, the family office of atai Founder and Chairman Christian Angermayer, with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1.
Mr. Angermayer commented: 鈥淲ith this financing, atai is well-positioned to accelerate its efforts and achieve its goal of delivering new therapeutic options for individuals facing serious mental health challenges. We are confident that these trial results will support a robust discussion with the FDA and allow us have a clear Phase 3 plan early in 2026. I am especially grateful for the repeated support of Ferring Ventures. Their deep understanding of commercialization, market dynamics, and how to build and run effective sales teams is invaluable for atai as it prepares to transform from a clinical-stage biotech into a fully integrated commercial company over time鈥�.
Jean-Frederic Paulsen, Chairman, Ferring Ventures S.A., added: 鈥淧sychedelics have demonstrated remarkable potential as a transformative class of treatments for a range of mental health conditions. atai has consistently led innovation and progress in this space, and I am pleased to expand our investment to support atai in pioneering the next generation of mental health treatments.鈥�
TD Cowen, Leerink Partners, Guggenheim Securities and Berenberg are acting as joint-lead placement agents for the private placement.
The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the 鈥淪ecurities Act鈥�), or any state鈥檚 securities laws, and will be issued and sold in a private placement in reliance on Section 4(a)(2) of the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. atai granted registration rights to the purchasers in the private placement, and has agreed to file a registration statement with the Securities and Exchange Commission (the 鈥淪EC鈥�) registering the resale of the common shares issued in the private placement and the Common Shares issuable upon exercise of the Pre-Funded Warrants issued in the private placement. The offer and sale of the Common Shares underlying the Pre-Funded Warrant have not been registered under the Securities Act.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai鈥檚 pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the 鈥淓xchange Act鈥�). The words 鈥渂elieve,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渆stimate,鈥� 鈥渃ontinue,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥渋nitiate,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥減roject,鈥� 鈥減lan,鈥� 鈥減otentially,鈥� 鈥減reliminary,鈥� 鈥渓ikely,鈥� and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, expectations regarding the closing of the private placement financing including satisfaction and timing of closing conditions, including the closing conditions relating to the HSR Act filing, and expectations regarding the use of proceeds from the proposed financing. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including important factors described in the section titled 鈥淩isk Factors鈥� in our most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in atai鈥檚 other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Contact Information
Investor Contact:
atai Media Contact:
FAQ
How much funding did atai Life Sciences (NASDAQ: ATAI) raise in its July 2025 private placement?
Who were the lead investors in atai's 2025 private placement financing?
What will atai Life Sciences use the $50 million financing proceeds for?
When is atai's private placement expected to close?
What are atai's plans following this financing round?
